Bone metastasis in Solid Tumor Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Bone metastasis in Solid Tumor market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Mabwell (Shanghai) Bioscience Co. Ltd., Novartis, Institut Bergonié ,Pfizer, GlaxoSmithKline, Amgen, QSAM Therapeutics Inc., Actuate Therapeutics Inc., Hoffmann-La Roche

[Nevada, United States] - DelveInsight's "Bone metastasis in Solid Tumor Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Bone metastasis in Solid Tumor, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Bone metastasis in Solid Tumor Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/bone-metastasis-in-solid-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Bone metastasis in Solid Tumor Market Report:
The Bone metastasis in Solid Tumor market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
In July, 2024: Actuate Therapeutics Inc. announced that GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
In July, 2024: NantCell, Inc. announced that AMG 479 is an investigational fully human monoclonal antibody that targets type 1 insulin-like growth factor receptor (IGF-1R). Signaling through IGF-1R plays an important role in the regulation of cell growth and survival.
According to the study of Shibata et al. (2016), a smaller study on autopsy cases recorded by the Shikoku Cancer Center in Japan indicated that the frequencies of bone metastasis varied among cancers; they were as high as 75% in cancers such as of the breast and prostate, and as low as 22% in stomach and colon cancers.
As per the study by Huang et al. (2020), the rate of bone metastases is 23.19% in SCLC, 22.50% in NSCLC (NOS/others), 20.28% in ADC, 8.44% in squamous cell arcinoma of the lung (SCC), and 4.11% in bronchioloalveolar carcinoma [NSCLC (BAC)].
According to the study of Hernandez et al. (2015), there were 330,000 (168,063 Medicare fee-for-service; 162,239 other) patients aged ≥18 years living with solid tumors and bone metastases in 2012.
Key Bone metastasis in Solid Tumor Companies are as follows: Mabwell (Shanghai) Bioscience Co. Ltd., Novartis, Institut Bergonié ,Pfizer, GlaxoSmithKline, Amgen, QSAM Therapeutics Inc., Actuate Therapeutics Inc., Hoffmann-La Roche
Key Bone metastasis in Solid Tumor Therapies are as follow: XOFIGO (Radium-223 dichloride), XGEVA/RANMARK (denosumab), Cabozantinib, MW032, Xgeva, Ibandronate, zoledronic acid, 9-ING-41, Doxorubicin, AMG 479
Launching multiple stage Bone metastasis in Solid Tumor pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Bone metastasis in Solid Tumor market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/bone-metastasis-in-solid-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Bone metastasis in Solid Tumor Overview:
Bone metastasis occurs when cancer cells spread from their original site to a bone. Nearly all types of cancer can spread (metastasize) to the bones. But some types of cancer are particularly likely to spread to bone, including breast cancer and prostate cancer.

Bone metastasis in Solid Tumor Epidemiology Segmentation:
The Bone metastasis in Solid Tumor market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Incident Cases of Bone Metastasis in Solid Tumors in the 7MM
Cases of Bone Metastasis by Solid Tumor type in the 7MM
Gender-specific Cases of Bone Metastasis in Solid Tumors in the 7MM

For more information about Bone metastasis in Solid Tumor companies working in the treatment market, visit: https://www.delveinsight.com/sample-request/bone-metastasis-in-solid-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Bone metastasis in Solid Tumor Market Insights
The secondary cancers within the bone are difficult to cure, but treatments are available to lessen the symptoms and lengthen life. Therapeutic strategies for metastatic bone cancers rely on treating the cancer cells, targeting the bone microenvironment, and providing palliative therapies to alleviate symptoms associated with bone metastasis. Therapies include bone-targeting agents (BTA) like zoledronic acid, pamidronate disodium, and XGEVA (denosumab), which are indicated to prevent SREs in patients with bone metastasis in the US, Europe and Japan.

Bone metastasis in Solid Tumor Drugs Uptake

Bisphosphonates are a type of medication that decreases pain from bone metastasis and help make bones stronger. They are used to treat or prevent osteoporosis, other bone diseases, and elevated blood calcium.
XGEVA (denosumab) is a RANK ligand inhibitor indicated to prevent SREs in patients with bone metastases from solid tumors. It is a fully human monoclnal antibody that binds to RANK Ligand, a protein essential for the formation, function, and survival of osteoclasts (the cells that break down bone).
XOFIGO (radium-223 dichloride) is an alpha particle-emittingradioactive therapeutic agent indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases, and no known visceral metastatic disease.
Radiation therapy is another palliative approach to treating bone metastasis. It is a non-invasive and effective way to improve pain from these lesions generally within 2-6 weeks of treatment.

Get your copy today and empower your strategy for better patient outcomes, Dive into our exclusive market research report for unparalleled insights into trends, innovations, and opportunities in this growing field @ https://www.delveinsight.com/sample-request/bone-metastasis-in-solid-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Bone metastasis in Solid Tumor Therapies and Key Companies:
XOFIGO (Radium-223 dichloride): Bayer HealthCare Pharmaceuticals
XGEVA/RANMARK (denosumab): Amgen
Cabozantinib: Exelixis
MW032, Xgeva: Mabwell (Shanghai) Bioscience Co., Ltd.
Ibandronate: Hoffmann-La Roche
zoledronic acid: Novartis
9-ING-41, Doxorubicin.: Actuate Therapeutics Inc.
AMG 479: NantCell, Inc.

Bone metastasis in Solid Tumor Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2020 to 2034. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Bone metastasis in Solid Tumor.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/bone-metastasis-in-solid-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Bone metastasis in Solid Tumor Market Drivers:
Increasing Incidence of Solid Tumors
Advancements in Diagnostic Imaging
Growth in Targeted Therapy Options
Increased Focus on Cancer Pain Management

Bone metastasis in Solid Tumor Market Barriers:
Limited Access to Advanced Diagnostic Tools
Side Effects and Complications of Current Therapies
Slow Adoption of New Therapies in Emerging Markets
Complexity of Treatment Regimens

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/bone-metastasis-in-solid-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Bone metastasis in Solid Tumor Market Report:
Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key Bone metastasis in Solid Tumor Companies: Mabwell (Shanghai) Bioscience Co. Ltd., Novartis, Institut Bergonié ,Pfizer, GlaxoSmithKline, Amgen, QSAM Therapeutics Inc., Actuate Therapeutics Inc., Hoffmann-La Roche
Key Bone metastasis in Solid Tumor Therapies: XOFIGO (Radium-223 dichloride), XGEVA/RANMARK (denosumab), Cabozantinib, MW032, Xgeva, Ibandronate, zoledronic acid, 9-ING-41, Doxorubicin, AMG 479
Bone metastasis in Solid Tumor Therapeutic Assessment: Current marketed and emerging therapies
Bone metastasis in Solid Tumor Market Dynamics: Bone metastasis in Solid Tumor Market drivers and Bone metastasis in Solid Tumor barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Bone metastasis in Solid Tumor Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Bone metastasis in Solid Tumor market outlook, drug uptake, treatment scenario, and epidemiology trends: https://www.delveinsight.com/sample-request/bone-metastasis-in-solid-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1 Key Insights
2 Report Introduction
3 Bone Metastasis in Solid Tumors Market Overview at a Glance
4 Executive Summary of Bone Metastasis in Solid Tumors
5 Key Events
6 Epidemiology and Market Forecast Methodology
7 Disease Background and Overview
9 Patient Journey
10 Epidemiology and Patient Population of Bone Metastasis in Solid Tumors in the 7MM
11 Marketed Therapies
12 Emerging Therapies
13 Bone Metastasis in Solid Tumors: 7MM Analysis
14 Unmet Needs
15 SWOT Analysis
16 KOL Views
17 Market Access and Reimbursement
18 Appendix
19 DelveInsight Capabilities
20 Disclaimer
21 About DelveInsight

List of Top Selling Market Research Reports in 2024

Surgical Energy Generators Market- https://www.delveinsight.com/report-store/surgical-energy-generators-market
Surgical Sealant Tissue Patch Market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Surgical Stapling Devices Market- https://www.delveinsight.com/report-store/surgical-stapling-devices-market
Vital Sign Monitoring Devices Market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Syphilis Market- https://www.delveinsight.com/report-store/syphilis-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Pelvic Organ Prolapse Market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
Scoliosis Market- https://www.delveinsight.com/report-store/scoliosis-market
SGLT2 Inhibitors Market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
Urinary Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Carcinoid Syndrome Market- https://www.delveinsight.com/report-store/carcinoid-syndrome-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Bone Growth Stimulators Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Skin Neoplasms Market- https://www.delveinsight.com/report-store/skin-neoplasms-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Lymphedema Market- https://www.delveinsight.com/report-store/lymphedema-market
Artificial Disc Market- https://www.delveinsight.com/report-store/artificial-disc-market
Exocrine Pancreatic Insufficiency Market- https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market
Overactive Bladder Market- https://www.delveinsight.com/report-store/overactive-bladder-oab-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
HDAC Inhibitors Market- https://www.delveinsight.com/report-store/hdac-inhibitors-market
Ventral Hernia Market- https://www.delveinsight.com/report-store/ventral-hernia-market
Facial Lines Market- https://www.delveinsight.com/report-store/facial-lines-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Microscopy Device Market- https://www.delveinsight.com/report-store/microscopy-device-market

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.